A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Sponsor: Arvinas Operations Inc.
Phase: 1, 2
Disease: Advanced solid tumors
EU trial number: 2026-525614-57-00
Population: Adults aged at least 18 years with advanced solid malignancies eligible for phase 1 dose escalation and dose optimization or phase 2 expansion of investigational ARV-6723 alone or with pembrolizumab, subject to protocol-defined prior therapy, performance status and organ function eligibility.
Register Investigator Interest
Interested in offering this trial to suitable patients?